OBJECTIVE: Infiltration of the central nervous system (CNS) by leukemia is a problematic disease manifestation of acute lymphoblastic leukemia (ALL). The mechanisms by which leukocytes interact with human brain-derived microvasculature endothelial cells (HBMEC) and enter the CNS are largely derived from models of inflammation. However, our data indicate that ALL cells do not elicit an inflammatory phenotype by HBMEC. Our current investigation focuses on the contribution of the unique coexpression of vascular endothelial (VE)-cadherin and platelet endothelial cell adhesion molecule-1 (PECAM-1) by ALL in mediating leukemic cell interactions with HBMEC as an in vitro model of the blood-brain barrier. MATERIALS AND METHODS: Primary ALL and ALL cell lines were evaluated for VE-cadherin and PECAM-1 expression. Lentiviral-mediated transduction of VE-cadherin and PECAM-1 into REH cells and antibody neutralization of VE-cadherin and PECAM-1 in SUP-B15 cells was used to delineate the role of these two proteins in mediating ALL adhesion to, and migration through, HBMEC monolayers. RESULTS: Although cell line models indicate that VE-cadherin and PECAM-1 expression is found on the surface Philadelphia chromosome-positive ALL, evaluation of primary ALL demonstrates that VE-cadherin and PECAM-1 are expressed independent of Philadelphia status. Expression of VE-cadherin and PECAM-1 by ALL enhanced the adhesion of ALL to HBMEC, while expression of PECAM-1 enhanced ALL adhesion to, and migration through, HBMEC. CONCLUSIONS: Expression of VE-cadherin and PECAM-1 by ALL cells positions them to interact with HBMEC. By increasing our understanding of molecular mechanisms through which ALL cells gain entry into the CNS, new strategies may be designed to prevent leukemia cell entry into the CNS.
OBJECTIVE: Infiltration of the central nervous system (CNS) by leukemia is a problematic disease manifestation of acute lymphoblastic leukemia (ALL). The mechanisms by which leukocytes interact with human brain-derived microvasculature endothelial cells (HBMEC) and enter the CNS are largely derived from models of inflammation. However, our data indicate that ALL cells do not elicit an inflammatory phenotype by HBMEC. Our current investigation focuses on the contribution of the unique coexpression of vascular endothelial (VE)-cadherin and platelet endothelial cell adhesion molecule-1 (PECAM-1) by ALL in mediating leukemic cell interactions with HBMEC as an in vitro model of the blood-brain barrier. MATERIALS AND METHODS: Primary ALL and ALL cell lines were evaluated for VE-cadherin and PECAM-1 expression. Lentiviral-mediated transduction of VE-cadherin and PECAM-1 into REH cells and antibody neutralization of VE-cadherin and PECAM-1 in SUP-B15 cells was used to delineate the role of these two proteins in mediating ALL adhesion to, and migration through, HBMEC monolayers. RESULTS: Although cell line models indicate that VE-cadherin and PECAM-1 expression is found on the surface Philadelphia chromosome-positive ALL, evaluation of primary ALL demonstrates that VE-cadherin and PECAM-1 are expressed independent of Philadelphia status. Expression of VE-cadherin and PECAM-1 by ALL enhanced the adhesion of ALL to HBMEC, while expression of PECAM-1 enhanced ALL adhesion to, and migration through, HBMEC. CONCLUSIONS: Expression of VE-cadherin and PECAM-1 by ALL cells positions them to interact with HBMEC. By increasing our understanding of molecular mechanisms through which ALL cells gain entry into the CNS, new strategies may be designed to prevent leukemia cell entry into the CNS.
Authors: Andrea Alter; Martin Duddy; Sherry Hebert; Katarzyna Biernacki; Alexandre Prat; Jack P Antel; Voon Wee Yong; Robert K Nuttall; Caroline J Pennington; Dylan R Edwards; Amit Bar-Or Journal: J Immunol Date: 2003-05-01 Impact factor: 5.422
Authors: Dario Marchetti; Yvonne Denkins; Jane Reiland; Andrea Greiter-Wilke; Jennifer Galjour; Brian Murry; Jason Blust; Madhuchhanda Roy Journal: Pathol Oncol Res Date: 2003-10-07 Impact factor: 3.201
Authors: Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Shumei Man; Eroboghene E Ubogu; Katherine A Williams; Barbara Tucky; Melissa K Callahan; Richard M Ransohoff Journal: Clin Dev Immunol Date: 2008
Authors: Simon J O'Carroll; Dan Ting Kho; Rachael Wiltshire; Vicky Nelson; Odunayo Rotimi; Rebecca Johnson; Catherine E Angel; E Scott Graham Journal: J Neuroinflammation Date: 2015-07-08 Impact factor: 8.322
Authors: Soo-Hyun Kim; Richard P Redvers; Lap Hing Chi; Xiawei Ling; Andrew J Lucke; Robert C Reid; David P Fairlie; Ana Carolina Baptista Moreno Martin; Robin L Anderson; Delphine Denoyer; Normand Pouliot Journal: Dis Model Mech Date: 2018-07-06 Impact factor: 5.758
Authors: Chitra D Mandyam; Emmanuel G Villalpando; Noah L Steiner; Leon W Quach; McKenzie J Fannon; Sucharita S Somkuwar Journal: Brain Sci Date: 2017-10-16